BOSTON (Thomson Financial) - Pfizer Inc. said Wednesday it agreed to settle
all of its patent litigation worldwide involving Lipitor with generics
manufacturer Ranbaxy Laboratories Ltd. of India.
Under the terms of the agreement, Ranbaxy will have a license to sell
generic versions of the cholesterol-lowering medicine Lipitor and Caduet in the
U.S., effective November 30, 2011. The agreement also provides a license for
Ranbaxy to sell generic versions of Lipitor on varying dates in seven additional
countries.
Caduet is a medicine that combines the active ingredients of Lipitor and
Norvasc and treats both high blood pressure and high cholesterol.
Shares of Pfizer, a New York-based drug manufacturer, rose 1.7% in premarket
trading to $18.02.
Greg Saulnier
gs/jw
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|